Oatmeal, Coreline Team Up on AI Lung Cancer Screening

Oatmeal Health and Coreline Soft, a publicly traded AI imaging leader from South Korea and the U.S., have partnered to co-develop and distribute AI-powered lung cancer screening solutions across the United States. The collaboration aims to expand equitable access to early detection and screening for communities most in need.

Lung cancer remains the deadliest cancer, claiming more lives than colon, breast, and prostate cancers combined, yet only 5.8% of eligible patients are screened, with underserved populations facing the greatest barriers. Oatmeal Health’s platform offers AI-powered, reimbursed, zero-cost screening solutions specifically for Federally Qualified Health Centers (FQHCs) and cancer centers. The company is already deploying these solutions in California, Arizona, Oklahoma, and Massachusetts, identifying and screening thousands of high-risk patients who might otherwise be missed, all without adding burden to clinical teams.

Coreline Soft’s technology is integrated into major U.S. health systems and supports a high volume of low-dose CT scans each year. Guided by Jim Baranski, Executive Director of the Lung Cancer Foundation of America, the partnership aligns clinical, advocacy, and payer stakeholders to ensure the solution can be scaled effectively.

The Oatmeal Health platform automates the workflow for patients and providers. AI identifies high-risk patients within electronic health records, nurse practitioners conduct virtual shared decision-making visits, and health centers can bill for scans using AI CPT codes (0721T), reimbursed at roughly $650 per scan. The zero-cost, zero-hassle model also includes a risk-based revenue-sharing agreement with providers.

The collaboration is projected to save an estimated $300,000 to $500,000 per early detection of lung cancer while increasing access to life-saving care. Oatmeal Health is raising capital to support national distribution, expand its FQHC footprint, and complete its FDA CADx submission, targeted for the first quarter of 2026.